The Life Raft Group is committed to enhancing the survival and quality of life for people living with Gastrointestinal Stromal Tumor (GIST), and other rare diseases, through patient-powered research, education and empowerment, and global advocacy efforts.
Other Programs Supported by The Life Raft Group:
PATIENT
Leverage patient perspective to drive innovative solutions in cancer research.
POWERED
Educate and empower patients to take a larger role in their care.
SCIENCE
Accelerate research outcomes through collaborative efforts.
FOR LIFE
Increase access to effective treatments worldwide.
Real World Evidence In Action
Traditional models for cancer research have resulted in many breakthrough treatments for patients, but it is not enough. The LRG’s approach to GIST research through real world evidence, relies on timely, accurate data from the patient’s perspective, with patient survival as the primary objective.
RECENT LRG DATA
Did you know that GIST is actually a family of cancers? Learn more about the science of GIST.
Update your Patient Registry Info.
Join The Life Raft Group.
Current GIST Clinical Trials.
Search the GIST Specialist Database.
Dr. Monica Anderson
Diagnosed in 2012 with Adult GIST.
Bella Rocco
Diagnosed in 2009 with Pediatric
(SDH-deficient) GIST.
HELP US SAVE LIVES
The Life Raft Group is a community and it is up to all of us to make a difference. There are many ways to help. We always need patient tissue and data in our GIST patient registry. Volunteering your time or making a monetary donation also helps us drive research forward and save lives.
News
Clinical Trials update for February 2011
Bayer initiates a randomized Phase III trial of Regorafenib in GIST: On January 10, 2011 Bayer Healthcare in Berlin, Germany announced the initiation of a randomized phase III trial of Regorafenib (BAY 73-4506) for Gastrointestinal Stromal Tumor patients.
LRG responds to recent Cancer Cell coverage
Yesterday, there were a series of news stories reporting on an article published by Cooke et al inCancer Cell. Unfortunately, the coverage gave misleading information which could suggest that patients should not take Gleevec (imatinib) or Sutent (sunitinib).
Have you ever thought about what your cancer looks like?
Two human cancer cells seen just before they divide into four cells, viewed at 100x magnification. From the Nikon International Small World Photomicrography [...]
Introducing…Alianza GIST!
The Latin American GIST Initiative now has a name...and a logo! Alianza GIST is a partnership of patient advocates representing ten Latin [...]
Michigan GISTers meet up!
Ellen Rosenthal, Michigan Local Group Coordinator, had this to say about their latest local group meeting, “In attendance at the September 23 [...]
Colorado GISTers meet!
According to Colorado Coordinator, Jerry Call, “The October Colorado meeting went very well. “There was some eating and drinking and lots of [...]
EU Cancer Patients Concerns Heard: Cancer Patient Mobility Moves Closer to a Reality
EU Cancer Patients Concerns Heard: Cancer Patient Mobility Moves Closer to a Reality. The following article was taken from a European Cancer Patient Coalition press [...]
FDA official wants to prosecute pharma execs
This article is excerpted from a Bloomberg News story. FDA to pharma: Review your marketing to make sure it’s not breaking the rules, [...]
Keep up with the latest news, events, and opportunities to help.
To contact The Life Raft Group, please call 973-837-9092
PARTNERS & AFFILIATIONS
